Gemcitabine versus FOLFIRINOX in patients with advanced hENT1+ve pancreatic adenocarcinoma.

被引：1
|
作者：
Calegari, Maria Alessandra
Orlandi, Armando
Indellicati, Giulia
Martini, Maurizio
Cocomazzi, Alessandra
Bagala, Cinzia
Zurlo, Valeria
Di Dio, Carmela
Barile, Rosalba
Monterisi, Santa
Cassano, Alessandra
Astone, Antonio
Barone, Carlo
机构：
[1] Policlin Univ A Gemelli, UOC Oncol Med, Rome, Italy
[2] Policlin Univ A Gemelli, Ist Anat Patol, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e15295
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15295
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma HENT1 positive: back to the future
    Calegari, M. A.
    Orlandi, A.
    Cocomazzi, A.
    Martini, M.
    Bagala, C.
    Indellicati, G.
    Zurlo, V.
    Monterisi, S.
    Di Dio, C.
    Barile, R.
    Di Salvatore, M. A.
    Basso, M.
    Cassano, A.
    Larocca, L. M.
    Barone, C.
    ANNALS OF ONCOLOGY, 2015, 26
  • [2] Neoadjuvant FOLFIRINOX and/or gemcitabine/nabpaclitaxel for advanced pancreatic adenocarcinoma.
    Turner, Keli
    Narayanan, Sumana
    Attwood, Kristopher
    Hochwald, Steven N.
    Iyer, Renuka V.
    Kukar, Moshim
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [3] Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse
    Orlandi, A.
    Calegari, M. A.
    Martini, M.
    Cocomazzi, A.
    Bagala, C.
    Indellicati, G.
    Zurlo, V.
    Basso, M.
    Cassano, A.
    Larocca, L. M.
    Barone, C.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (10): : 988 - 995
  • [4] Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse
    A. Orlandi
    M. A. Calegari
    M. Martini
    A. Cocomazzi
    C. Bagalà
    G. Indellicati
    V. Zurlo
    M. Basso
    A. Cassano
    L. M. Larocca
    C. Barone
    Clinical and Translational Oncology, 2016, 18 : 988 - 995
  • [5] Efficacy and safety of FOLFIRINOX in elderly patients with advanced pancreatic adenocarcinoma.
    Jung, Jae Hyup
    Kang, Jingu
    Lee, Jong-Chan
    Hwang, Jin-Hyeok
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] FOLFIRINOX and gemcitabine/nab-paclitaxel efficacy in the treatment of locally advanced unresectable pancreatic adenocarcinoma.
    Bednar, Filip
    Ocuin, Lee Mayer
    Steve, Jennifer
    Zenati, Mazen S.
    Winters, Sharon
    Hogg, Melissa Ellen
    Bahary, Nathan
    Zeh, Herbert J.
    Zureikat, Amer H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [7] Neoadjuvant FOLFIRINOX and/or Gemcitabine/Abraxane for Advanced Pancreatic Adenocarcinoma
    Turner, K.
    Narayanan, S.
    Attwood, K.
    Iyer, R.
    Kuvshinoff, B.
    Hochwald, S.
    Kukar, M.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 : S118 - S119
  • [8] Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma
    Gilabert, Marine
    Chanez, Brice
    Rho, Young Soo
    Giovanini, Marc
    Turrini, Olivier
    Batist, Gerald
    Kavan, Petr
    Raoul, Jean Luc
    MEDICINE, 2017, 96 (16)
  • [9] Docetaxel/gemcitabine followed by gemcitabine and radiotherapy in patients with pancreatic adenocarcinoma.
    Pipas, JM
    Barth, RJ
    Zaki, B
    Colacchio, TA
    Gordon, SR
    Sutton, JE
    Ripple, GH
    Tsapakos, MJ
    Cates, JM
    Perez, RP
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 340S - 340S
  • [10] FOLFIRINOX FOR LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA. RESULTS OF AN AGEO MULTICENTRIC PROSPECTIVE STUDY
    Marthey, L.
    Sa-Cunha, A.
    Blanc, J. F.
    Cueff, A.
    Francois, E.
    Trouilloud, I.
    Malka, D.
    Bachet, J.
    Coriat, R.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 238 - 238
12345